Consumer Defensive · Household & Personal Products · Synthos Deep Dive · 2026-07-03
| Verdict | Hold — systematic Synthos tier |
| Price (2026-07-02) | $97.26 · market cap ~$11.8B |
| Synthos scores (0–10) | Downside Risk 6 · Growth Quality 3 · Exponential Potential 1 |
| Synthos fair value (base case) | ~$103 → +6% · full range $80 (bear) – $128 (bull) |
| Street consensus | $105.5 (high $139 / low $83; 0 Strong Buy · 4 Buy · 18 Hold · 6 Sell) — context, not our anchor |
| Valuation | 15.7× trailing EPS · ~17.6× FY26E · 15.7× FY27E · 13.3× FY30E · EV/S 2.2× · EV/EBITDA 11.5× |
| Dividend | ~5.1% yield, $4.96/yr, ~80% TTM payout — the core reason to own it |
| Exponential Potential | 1/10 · Very Low — flat ~$7B revenue for a decade, saturated TAM, no acceleration; a staple, not a growth story |
| Technicals | Downtrend — $97, −26% off 52-wk high, below the 200-DMA, RSI 48, −21% 12-mo (SPY +21%) |
| Conviction | Low / none — 0 expert voices in the Synthos KB; call rests entirely on fundamentals & quant |
| Position sizing | Income sleeve only, ~1–2% if owned for the dividend; not a growth holding |
| Next catalyst | 2026-07-30 Q4 FY26 earnings (Street EPS $1.64, rev ~$1.91B) |
| Single biggest risk | Secular volume stagnation + private-label share loss while the ~90% payout limits reinvestment |
One-line thesis. Clorox is a high-quality, low-beta consumer-staples franchise (Clorox bleach, Glad, Kingsford, Brita, Burt's Bees, Hidden Valley, now Purell) throwing off a ~5% dividend — but it is essentially ex-growth (revenue ~$7B for a decade), is guiding to a ~6% sales decline and ~9% organic decline in FY26, carries real leverage (2.5× net-debt/EBITDA, negative book equity from buybacks), and trades right at fair value with the stock in a genuine downtrend. This is a Watch — a yield holding, not a compounder or an exponential.
Clorox makes the everyday household stuff you already know: Clorox bleach and wipes, Glad trash bags, Kingsford charcoal, Brita filters, Burt's Bees, Hidden Valley Ranch, and — as of April 2026 — Purell hand sanitizer. It's the definition of a "boring, defensive" business: people buy these products in good times and bad.
Is the stock cheap or expensive? About fairly priced — neither a bargain nor a bubble. You're paying roughly what it's worth. The main reason to own it is the dividend of about 5% a year, which is real cash in your pocket.
The verdict is Watch: a fine, steady company, but it's barely growing — sales have been stuck around $7 billion for ten years, and this year management expects sales to actually shrink. So there's little reason to expect the stock price to climb much.
Here's what the three scores mean in everyday terms:
The one big worry: shoppers keep trading down to cheaper store-brand ("private label") versions, and Clorox's markets aren't growing — so the company has to fight just to stay flat, while paying out most of its profit as dividends leaves little to reinvest.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 55.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = CLX · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
The Clorox Company (NYSE: CLX) is a ~110-year-old (founded 1913) global maker of consumer and professional household products, headquartered in Oakland, CA, run by CEO Linda Rendle. Fiscal year ends June 30. It reports four segments:
Revenue by segment (FY2025, from filings):
By geography (FY2025): United States $6.08B (~86%) · Foreign $1.02B (~14%). This is an overwhelmingly US-domestic business — a stability strength but with little geographic growth diversification.
The strategic story of the moment is threefold: (a) a multi-year ERP/digital transformation that has distorted shipment timing (the swing factor in FY25→FY26 comparisons), (b) the April 2026 acquisition of GOJO Industries, adding the Purell hand-sanitizer franchise, and (c) an ongoing effort to recover market share lost after the 2023 cyberattack and post-COVID demand normalization.
There is none in the Synthos KB. The expert-claims file for CLX shows total_claims: 0, net_bullish_voices: 0, and an empty top array. No Synthos-tracked expert voice — bull or bear — currently covers Clorox.
What this means for the verdict: unlike a conviction-track name, this call is entirely fundamentals- and quant-driven. There is no independent expert breadth to lean on, and — per house standard — we will not manufacture conviction we do not have. The absence of coverage is itself mildly informative: Clorox is a slow, well-understood staple that the high-alpha voices Synthos tracks simply aren't excited about. Treat every judgment below as our own model reconciled to the reported financials and Street estimates, nothing more.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Low beta (0.53) and staple demand cut both ways, but net-debt/EBITDA 2.5×, negative book equity (buybacks + goodwill), a ~5% dividend at a ~80–90% payout, and a −59% max drawdown from peak are real fragility. Not a fortress balance sheet. |
| Growth Quality | 3 · Weak | ROIC ~17% and 44% gross margin show quality operations, but revenue has been flat at ~$7B for a decade and FY26 is guided down ~6% (organic −9%). Forward EPS CAGR is only ~7% and that's off a depressed trough. |
| Exponential Potential | 1 · Very Low | Mature company, saturated categories, no acceleration — the second derivative is flat-to-negative. There is no honest path to a multibagger here. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | ERP disruption fully laps, Purell/GOJO integrates cleanly and accretes, market-share recovery takes hold, margin rebuilds toward 45%+. FY27E EPS beats to ~$6.75; multiple re-rates to a staple-premium ~19×. | ~$128 (+32%) |
| Base (our anchor) | FY26 trough (EPS ~$5.53) gives way to a normalized recovery; FY27E EPS ~$6.20 (consensus); a flat-to-low-single-digit grower with a secure ~5% yield earns a ~16.5× forward multiple. | ~$103 (+6%) |
| Bear | Private-label share loss persists, organic declines don't reverse, GOJO integration disappoints, margins stay pressured by input/logistics/energy costs. FY27E EPS misses to ~$5.70; multiple de-rates to ~14×. | ~$80 (−18%) |
Synthos fair value = the base case, ~$103 (+6%), with the full $80–$128 span as the honest range. This anchor sits essentially on top of the Street's $105.5 consensus — we see no informational edge that justifies deviating, and a modest ~6% upside plus a ~5% dividend is a total-return story, not a capital-appreciation one. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). CLX is neither an exponential nor even a fast compounder — it is a mature, ex-growth staple:
Exponential Potential: Very Low (1/10). Own CLX for a defensive ~5% yield and low volatility, never for growth. This is the honest opposite of a flagship next-exponential.
CLX is roughly fairly valued. Trailing 15.7× EPS, 11.5× EV/EBITDA, and 2.2× EV/sales are all near the low end of the household-products peer range — appropriate for a no-growth name. On forward estimates the P/E is ~17.6× (FY26E, trough) → 15.7× (FY27E) → 13.3× (FY30E) — the multiple looks cheaper on out-years mainly because FY26 EPS is depressed by the ERP reversal, not because earnings are compounding fast.
The PEG is unfavorable (~1.5–1.9×) precisely because growth is so slow: you are not being paid to wait via appreciation. The real return here is the ~5.1% dividend, and the total-return case is roughly "5% yield + low-single-digit earnings growth + ~6% to fair value." FMP's letter rating is "B" (overall score 3/5) with weak marks on ROE-adjusted-for-leverage, debt/equity, and price/book — consistent with our read.
Street targets (context, not our anchor): consensus $105.5, high $139, low $83; the analyst tape is a clear Hold (0 Strong Buy, 4 Buy, 18 Hold, 6 Sell). Our $103 base FV sits essentially on top of consensus — we see no edge to justify a more aggressive call. Not a value buy; a fairly-priced income holding.
Clorox's moat is brand equity + shelf-space/scale in staple categories: the Clorox trademark itself is category-defining in bleach and disinfecting; Glad, Kingsford, Brita, Burt's Bees and Hidden Valley are strong #1/#2 brands. That supports pricing power and durable ~44% gross margins. But the moat is mature and under quiet erosion: private-label/store-brand competition in bags, litter, and cleaning steadily pressures volume and mix (Q3 FY26 showed volume-led weakness in Lifestyle and unfavorable price/mix in Health & Wellness). The categories don't grow, so the fight is defensive share retention, not expansion. The GOJO/Purell add is a sensible bolt-on into professional hygiene but is EBITDA-margin-neutral and modestly EPS-dilutive near term.
Peer set (market cap): Church & Dwight $23.4B (the closest household-products comp), Brown-Forman $12.2B, McCormick $14.4B, Hormel $13.8B, J.M. Smucker $12.4B, Coca-Cola Consolidated $15.4B, BJ's Wholesale $11.4B, Performance Food Group $17.8B, Somnigroup $16.5B. Within staples, CLX is a middling grower at a middling multiple — neither the premium compounder (CHD) nor a deep-value turnaround.
- Net sales down ~6% (including ~3 pts positive from the GOJO acquisition, <1 pt negative from the VMS divestiture, offset by <1 pt favorable FX) — worse than the prior "low end of −6% to −10%" framing.
- Organic sales down ~9% (vs prior low end of −5% to −9%), including ~7.5 pts of drag from reversing the prior-year ERP-transition inventory build.
- Gross margin down 250–300 bps (materially worse than the prior −50 to −100 bps), citing GOJO transaction costs (~60bps), the ERP shipment reversal (~100bps), and higher energy costs tied to Middle East conflict.
- Management frames the FY26 EPS hit as ~30% to diluted EPS / ~23% to adjusted EPS vs the elevated FY25 base, driven mainly by the transitory ERP inventory drawdown (~90¢ EPS). CEO Rendle: results "mixed," "more work to do in a challenging consumer and cost environment," with confidence in "more consistent, profitable growth over time" once ERP/Purell normalize.
- Honest weighting: this is management's self-interested framing. The bull reading is that most of the FY26 weakness is transitory (ERP timing) and reverses in FY27; the bear reading is that organic declines and gross-margin erosion are real and only partly explained by timing. We give it half-weight, as designed.
Thesis tripwires (what would change the call): organic sales failing to inflect positive in FY27; gross margin failing to recover toward 45%; a dividend-coverage scare (FCF below the payout for consecutive years); or GOJO integration proving dilutive beyond guidance. A clean ERP lap + margin recovery + share stabilization would upgrade this toward a Buy — Tactical.
Watch. Clorox is a genuinely high-quality, low-beta staple franchise with a ~5% dividend — but it is ex-growth (flat revenue for a decade, guided down in FY26), carries more leverage and less balance-sheet flexibility than its defensive reputation implies (2.5× net-debt/EBITDA, negative book equity), and trades right at fair value with the stock in a real downtrend (−26% off highs, below the 200-DMA, −21% vs a +21% SPY). With ~6% upside to a $103 base FV plus the dividend, the total-return case is a hold-for-income story, not a buy-for-appreciation one — and there is no expert conviction in the Synthos KB to argue otherwise.